# DJI136

Source: https://onco.cc/drugs/dji136/  
OnCo record `dji136` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DJI136 is an experimental CAR-T cell therapy from Novartis Pharmaceuticals in phase 2 trials for non-small-cell lung cancer, aimed at DLL3.

## Summary

DJI136 is a CAR-T cell therapy developed by Novartis Pharmaceuticals. Its target is DLL3 (the sponsor names DLL3). The sponsor states: DLL3-targeted chimeric antigen receptor (CAR) T-cell therapy administered by intravenous infusion. ClinicalTrials.gov describes the intervention as: DLL3 targeted CAR-T therapy administered by intravenous (i.v.) infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07564401, plans to enrol 80 participants with primary completion expected 2031-03-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: DLL3-targeted chimeric antigen receptor (CAR) T-cell therapy administered by intravenous infusion.

## Sources

- ClinicalTrials.gov: trials of DJI136: https://clinicaltrials.gov/search?intr=DJI136

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [DLL3](https://onco.cc/targets/dll3/)
- companies: [Novartis](https://onco.cc/companies/novartis/)
- trials: [A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy](https://onco.cc/trials/nct07564401/)

---
JSON: https://onco.cc/api/v1/entities/dji136.json